The short answer: triple-negative breast cancer (TNBC) is harder to treat because it lacks all three of the main targets that doctors use to fight other breast cancers. It has no estrogen receptor, no progesterone receptor, and no HER2 protein [6]. This means hormone therapies and HER2-targeted drugs, which are highly effective in other subtypes, do not work. For decades, chemotherapy was the only systemic option. TNBC is also more aggressive: it grows faster, is more likely to spread, and has a higher rate of early recurrence than other breast cancers [6][12]. It is more common in younger women and in women of African and Indian descent [6]. However, 2026 brought a major breakthrough with a new antibody-drug conjugate that nearly doubled survival in advanced TNBC [3][8].
Triple-negative breast cancer accounts for about 10% to 20% of all breast cancers [3][12]. It is not a single disease. It is a group of cancers that share a common feature, the absence of three receptors, but differ in their biology and behaviour [1][12].
This article explains what makes TNBC harder to treat, why it behaves differently, and what the latest research says about new treatments.
What “triple-negative” means
When a breast cancer is diagnosed, the tumour is tested for three markers: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [6].
Most breast cancers have at least one of these markers. Hormone receptor-positive cancers have ER or PR, which means hormones fuel their growth. These can be treated with drugs like tamoxifen that block hormones. HER2-positive cancers have too much HER2 protein, which drives rapid growth. These can be treated with targeted drugs like trastuzumab.
Triple-negative breast cancer tests negative for all three [6]. This means doctors have no receptor to target. Hormone therapy and HER2-targeted drugs are useless. Until recently, chemotherapy was the only systemic treatment available [1][11].
Why TNBC is more aggressive
TNBC is not just harder to treat because of what it lacks. It also behaves more aggressively from the start.
Dr. Roberto Leon Ferre of Mayo Clinic explains that TNBC “tends to spread at a microscopic level from the beginning” [6]. This means that by the time it is detected, cancer cells may already have escaped the breast, even if imaging shows a localised tumour. This is why chemotherapy is almost always given before surgery for TNBC, to treat the whole body systemically [6].
A landmark study by Dent and colleagues compared TNBC to other breast cancer subtypes. At a median follow-up of 8 years, women with TNBC were more likely to experience distant recurrence (hazard ratio 2.6, p < 0.0001) and had inferior survival (hazard ratio 3.2, p < 0.001) within 5 years of diagnosis [12].
The pattern of recurrence is also distinct. In TNBC, the risk of recurrence peaks at around 3 years after diagnosis and then declines. In other breast cancers, the risk is lower initially but remains constant over time [12]. This means TNBC is most dangerous in the first few years.
TNBC is not one disease
One of the challenges in treating TNBC is that it is highly heterogeneous. Research has shown that TNBC can be divided into multiple molecular subtypes with different biology and different responses to treatment [12].
Lehmann and colleagues analysed gene expression from over 500 TNBC tumours and identified six distinct subtypes: two basal-like subtypes (BL1 and BL2), an immunomodulatory subtype (IM), a mesenchymal subtype (M), a mesenchymal stem-like subtype (MSL), and a luminal androgen receptor subtype (LAR) [12].
This heterogeneity means that a treatment that works for one TNBC patient may not work for another. It also means that clinical trials need to account for these differences, which complicates the development of new drugs [17].
Why traditional targeted therapies do not work
The defining feature of TNBC is the absence of targets. This has several consequences.
No hormone therapy. Drugs like tamoxifen and aromatase inhibitors work by blocking estrogen or reducing its production. TNBC cells do not have estrogen receptors, so these drugs have nothing to bind to [6].
No HER2-targeted therapy. Drugs like trastuzumab (Herceptin) work by attaching to the HER2 protein on cancer cells. TNBC cells do not have excess HER2, so these drugs are not effective [6].
Reliance on chemotherapy. For decades, chemotherapy was the only systemic option. TNBC cells divide rapidly, which makes them sensitive to chemotherapy drugs that kill dividing cells [1]. But chemotherapy is non-specific. It damages healthy cells too, causing side effects like hair loss, nausea, and fatigue. And not all TNBC responds to it [8].
The immunotherapy limitation
Immunotherapy has helped some TNBC patients, but only a minority. Pembrolizumab, a PD-1 inhibitor, is approved for early-stage TNBC at high risk of recurrence and for advanced TNBC that expresses PD-L1 [6].
However, only about 30% of TNBC patients are eligible for immunotherapy based on PD-L1 expression. About 70% of patients with advanced TNBC are not candidates for immunotherapy and face poor prognosis with chemotherapy alone [3][8].
A 2025 review noted that TNBC shows only “modest responsiveness” to PD-1/PD-L1 inhibitors compared to some other cancer types, and resistance remains a major barrier [2].
The 2026 breakthrough: Dato-DXd
The most significant recent advance for TNBC is a new class of drug called an antibody-drug conjugate (ADC). These drugs combine a targeted antibody with a potent chemotherapy payload, delivering the toxic drug directly to cancer cells while sparing healthy tissue.
The TROPION-Breast02 trial tested datopotamab deruxtecan (Dato-DXd) in 644 patients with previously untreated, advanced TNBC who were not eligible for immunotherapy [3][8].
The results, published in Annals of Oncology in April 2026, were striking:
| Outcome | Dato-DXd | Chemotherapy |
|---|---|---|
| Median progression-free survival | 10.8 months | 5.6 months [3] |
| Median overall survival | 23.7 months | 18.7 months [3] |
| Overall response rate | 63% | 29% [8] |
| Median duration of response | 12.3 months | 7.1 months [8] |
Dr. Tiffany Traina, the U.S. lead investigator, noted that historic median overall survival for this patient group has been about 12 months. The trial showed 23.7 months with Dato-DXd, nearly double [3].
Dato-DXd targets TROP2, a protein that is overexpressed in TNBC cells [3]. It is the first TROP2-directed ADC to show superiority over chemotherapy in the first-line setting for TNBC patients ineligible for immunotherapy [13].
What is myth, not documented
Myth: TNBC is always fatal. TNBC is aggressive, but it is treatable. Patients who achieve a pathological complete response after neoadjuvant chemotherapy have good outcomes [12]. New treatments like Dato-DXd are improving survival [3][8].
Myth: TNBC is a single disease. TNBC is highly heterogeneous, with at least six molecular subtypes identified [12]. This is why treatments work differently for different patients.
Myth: Chemotherapy is useless for TNBC. Chemotherapy remains essential, especially for early-stage disease. TNBC cells divide rapidly, making them sensitive to chemotherapy. The problem is that chemotherapy alone is not enough for many patients [6][8].
Myth: Immunotherapy works for all TNBC patients. Only about 30% of TNBC patients are eligible for immunotherapy based on PD-L1 expression. The majority are not candidates [3][8].
The bottom line
Triple-negative breast cancer is harder to treat because it lacks the three main targets that doctors use to fight other breast cancers. It is also more aggressive, spreading early and recurring within the first few years. It is not one disease but a group of heterogeneous cancers. For decades, chemotherapy was the only option, and immunotherapy helps only a minority. The 2026 approval of Dato-DXd, an antibody-drug conjugate, represents a major step forward, nearly doubling survival in advanced TNBC for patients who previously had few options. Research into new targets and new drug classes continues.
Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice. If you have been diagnosed with triple-negative breast cancer, discuss your treatment options with a qualified healthcare provider. We welcome your feedback and corrections. Please contact us if you notice any errors.
References
[1] Triple negative breast cancers: Clinical and prognostic implications, ScienceDirect. https://www.sciencedirect.com/science/article/abs/pii/S0959804909700139
[2] Recent findings on the PD-1/PD-L1 Axis in breast cancer: Molecular mechanisms, immunotherapeutic potentials, and clinical implications, ScienceDirect. https://www.sciencedirect.com/science/article/abs/pii/S1040842825003774
[3] Landmark Study Makes Dato-DXd First Line in Hard-to-Treat Triple Negative Breast Cancer, Memorial Sloan Kettering Cancer Center. https://www.mskcc.org/clinical-updates/landmark-study-makes-dato-dxd-first-line-in-hard-to-treat-triple-negative-breast-cancer
[4] Balancing Risks and Benefits of Adjuvant Chemotherapy in Small-Size Triple-Negative Breast Cancer, ASCO Daily News. https://dailynews.ascopubs.org/do/balancing-risks-and-benefits-adjuvant-chemotherapy-small-size-triple-negative-breast
[5] Prospective analysis of pre-diagnostic untargeted plasma metabolomics and risk of triple-negative breast cancer in the EPIC study, International Agency for Research on Cancer. https://www.iarc.who.int/news-events/prospective-analysis-of-pre-diagnostic-untargeted-plasma-metabolomics-and-risk-of-triple-negative-breast-cancer-in-the-european-prospective-investigation-into-cancer-and-nutrition-epic/
[6] Understanding triple-negative breast cancer and its treatment, Mayo Clinic News Network. https://newsnetwork.mayoclinic.org/discussion/understanding-triple-negative-breast-cancer-and-its-treatment/
[7] Targeting Triple-Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements, Wiley Online Library. https://onlinelibrary.wiley.com/doi/10.1002/cam4.70803
[8] Global trial shows novel treatment for triple-negative breast cancer nearly doubles survival, SingHealth. https://www.singhealth.com.sg/news/patient-care/global-trial-shows-novel-treatment-for-triple-negative-breast-cancer-nearly-doubles-survival
[9] Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement, Elsevier. https://mdanderson.elsevierpure.com/en/publications/tailoring-treatment-to-cancer-risk-and-patient-preference-the-202/
[10] Triple negative breast cancer distribution by age and stage, WHO EMRO. https://applications.emro.who.int/emhj/fulltext/1020-3397-2021-2706-530-683-eng.pdf
[11] Triple-negative breast cancer: therapeutic options, ScienceDirect. https://www.sciencedirect.com/science/article/abs/pii/S1470204507700748
[12] The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics, ASCO Publications. https://ascopubs.org/doi/pdfdirect/10.1200/EDBK_159135
[13] Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape, ASCO Publications. https://ascopubs.org/doi/pdfdirect/10.1200/EDBK-26-520506
[14] Triple-negative breast cancer: 2025 consensus guidelines, BVS. https://busqueda.tmgl.org/portal/resource/pt/biblio-1664357
[15] BRCA1 expression and triple-negative breast cancer, WHO IMSEAR. https://imsear.searo.who.int/server/api/core/bitstreams/e8c1d5cc-4803-4e42-b8cc-769ce5d0eca4/content
[16] The nature of triple-negative breast cancer classification and antitumoral strategies, Europe PMC. https://europepmc.org/article/pmc/7808875
[17] Advanced strategies for targeting severe triple-negative breast cancer, ScienceDirect. https://www.sciencedirect.com/science/chapter/edited-volume/abs/pii/B9780443333491000077
[18] Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers, PubMed. https://s2.ipubmed.cn/41716468/
